On Thursday, Chanticleer Holdings, Inc. (NASDAQ:HOTR)’s shares climbed, as owner and operator of multiple restaurant brands internationally and domestically, is happy to declare that the corporation will be presenting at the 2ndAnnual Growth Capital Expo being held on April 12-14, 2015 at Caesars Palace in Las Vegas, NV. CEO of Chanticleer Holdings, Mike Pruitt will be presenting on Monday, April 13, 2015 at 4:30 pm PT.
The Growth Capital Expo is three conferences in one with presentations by selected MicroCap and pre-IPO growth companies; two full days of educational panels and presentations by the leading practitioners of investment in public and late-stage private emerging growth companies; and a half-day pre-conference public corporation boot camp designed specifically for executive managers of pre-IPO and recently public companies seeking to hone their skills at choosing board members and advisors, negotiating with investors, market messaging and corporate governance.
Chanticleer Holdings, Inc. owns and operates Hooters franchises in the United States and internationally. The corporation’s Hooters restaurants are casual beach-themed establishments with sports on television, jukebox music, and the Hooters Girls facilities.
Rosetta Genomics, Ltd. (NASDAQ:ROSG)’s shares jumped, during the last trading session on Thursday, after a leading developer and provider of microRNA-based and other molecular diagnostics, declared it has agreed to attain CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation, a Fjord Ventures portfolio corporation. The attainment of PersonalizeDx by Rosetta Genomics is predictable to close within the next several weeks and is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.
PersonalizeDx is a rapidly growing molecular diagnostics and services corporation serving community-based pathologists, urologists, oncologists and other reference laboratories across the U.S. Through this transaction Rosetta Genomics will gain proprietary tests in prostate, bladder and lung cancer, strong commercial and laboratory operations capabilities and a state-of-the-art, high-complexity CLIA laboratory in Lake Forest, California.
The purchase price comprises $2.0 million in cash, 500,000 ordinary shares of Rosetta Genomics Ltd., some specified assets and certain services to be offered by Rosetta Genomics to Prelude Corporation. In connection with this transaction Rosetta Genomics will gain rights to market Prelude’s novel assay for ductal carcinoma in situ (DCIS).
Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA.
At the end of Thursday’s trade, Inuvo, Inc. (NYSEMKT:INUV)’s shares climbed, after a digital publishing and advertising technology corporation, declared that the expansion in both its digital publishing and ad-tech business segments over the last year has caused the Corporation to outgrow its current office. As a result, Inuvo has signed a five-year lease for office space in Little Rock, Arkansas that will effectively double its current office space to nearly 13,000 sf. The corporation will be relocating the majority of its 53 employees to a new facility at 500 President Clinton Ave. in Little Rock, Arkansas. The Corporation anticipates to move into the new facility later this year.
Inuvo, Inc., together with its auxiliaries, operates as an Internet marketing and technology corporation that delivers advertisements through various networks of Websites and applications reaching desktop and mobile devices in the United States.
Apogee Enterprises, Inc. (NASDAQ:APOG), ended its Thursday’s trading session in Green, after Apogee declared fiscal 2015 fourth-quarter and full-year results. Apogee provides distinctive solutions for enclosing commercial buildings and framing art.
FY15 FOURTH QUARTER VS. PRECEDING-YEAR PERIO:
- Proceeds of $246.7 million were up 15 percent.
- Operating revenue of $19.6 million was up 62 percent.
- Earnings per share of $0.47 were up 74 percent.
- Backlog of $490.8 million was up 49 percent.
- Cash and short-term investments were $52.5 million.
FY15 FULL YEAR VS. PRECEDING-YEAR PERIOD:
- Proceeds of $933.9 million were up 21 percent.
- Operating revenue of $63.6 million was up 58 percent.
- Adjusted earnings per share of $1.50 were up 58 percent.
- Stated EPS was $1.72, counting the $0.22 per share tax credit in the second quarter.
Apogee Enterprises, Inc., together with its auxiliaries, designs and develops glass solutions for enclosing commercial buildings and framing art primarily in the United States, Canada, and Brazil. The corporation operates through four segments: Architectural Glass, Architectural Services, Architectural Framing Systems, and Large-Scale Optical Technologies (LSO).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
